Selegiline ameliorates depression-like behaviors in rodents and modulates hippocampal dopaminergic transmission and synaptic plasticity
•Repeated selegiline injection reduces immobility time in rodent depression tests.•Antidepressant-like action of selegiline is independent of MAO-A inhibition.•Selegiline increases DA content and prevents LTP impairment in the hippocampus. Selegiline, an irreversible inhibitor of monoamine oxidase (...
Gespeichert in:
Veröffentlicht in: | Behavioural brain research 2019-02, Vol.359, p.353-361 |
---|---|
Hauptverfasser: | , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 361 |
---|---|
container_issue | |
container_start_page | 353 |
container_title | Behavioural brain research |
container_volume | 359 |
creator | Ishikawa, Toshiko Okano, Motoki Minami, Akiko Tsunekawa, Hiroko Satoyoshi, Hiroshi Tsukamoto, Yuka Takahata, Kazue Muraoka, Shizuko |
description | •Repeated selegiline injection reduces immobility time in rodent depression tests.•Antidepressant-like action of selegiline is independent of MAO-A inhibition.•Selegiline increases DA content and prevents LTP impairment in the hippocampus.
Selegiline, an irreversible inhibitor of monoamine oxidase (MAO)-type B, is widely prescribed for Parkinson’s disease and, at higher doses, for major and atypical depression, whereby it is non-selectively inhibitory to both MAO-A and MAO-B activities. MAO inhibitors have been considered to function as antidepressants through MAO-A inhibition. We have previously reported that selegiline exerts antidepressant-like effects in the mouse forced swim test (FST) via dopamine D1 receptor activation. Our objective was to elucidate the mechanisms underlying the antidepressant-like effects of selegiline. We also tested another propargylamine MAO-B inhibitor, rasagiline. Triple subcutaneous injection (at 24, 5, and 1 h prior to behavioral testing) with selegiline (10 mg/kg/injection), but not rasagiline (1, 3, or 10 mg/kg/injection), reduced the immobility time in the mouse FST and rat tail suspension test. In the hippocampus and prefrontal cortex of mice subjected to the FST, selegiline and rasagiline completely inhibited MAO-B activities. However, selegiline suppressed MAO-A activities and monoamine turnover rates at a lesser degree than rasagiline at the same doses, indicating that the antidepressant-like effects of selegiline are independent of MAO-A inhibition. Moreover, selegiline, but not rasagiline, increased the hippocampal dopamine content. A single subcutaneous administration of 10 mg/kg selegiline, but not of rasagiline, significantly prevented hippocampal CA1 long-term potentiation impairment, induced by low-frequency stimulation prior to high-frequency stimulation in rats. These results suggest that the antidepressant-like effects of selegiline are attributable to enhancement of dopaminergic transmission and prevention of the impairment of synaptic plasticity in the hippocampus. |
doi_str_mv | 10.1016/j.bbr.2018.10.032 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2126911073</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S016643281831235X</els_id><sourcerecordid>2126911073</sourcerecordid><originalsourceid>FETCH-LOGICAL-c396t-f55987bfeb1db98ea5db051eb824d3cd0a4bca765d800463dc8c8f4a0a3b18c63</originalsourceid><addsrcrecordid>eNp9kM1uFDEQhC0EIpvAA3BBPnKZxR7Pj0ecUBQgUiQOwNlq2z2JF49t7NlI-wS8Nt7dwJFTy-6qUtdHyBvOtpzx4f1uq3XetozL-t4y0T4jGy7Hthn7bnpONlUzNJ1o5QW5LGXHGOtYz1-SC8FEPw1duyG_v6HHe-ddQAoLehczrFioxZSxFBdD491PpBof4LEuC3WB5mgxrIVCsHSJdu9PlgeXUjSwJPDUxgRLzcz3ztA1QyiLO6WdPOUQIK11kzyUOt16eEVezOALvn6aV-THp5vv11-au6-fb68_3jVGTMPazH0_yVHPqLnVk0Tora6VUMu2s8JYBp02MA69lbXsIKyRRs4dMBCaSzOIK_LunJty_LXHsqp6mEHvIWDcF9Xydpg4Z6OoUn6WmhxLyTirlN0C-aA4U0f-aqcqf3Xkf_yq_Kvn7VP8Xi9o_zn-Aq-CD2cB1pKPDrMqxmEwaF1Gsyob3X_i_wC6MZrR</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2126911073</pqid></control><display><type>article</type><title>Selegiline ameliorates depression-like behaviors in rodents and modulates hippocampal dopaminergic transmission and synaptic plasticity</title><source>Elsevier ScienceDirect Journals</source><creator>Ishikawa, Toshiko ; Okano, Motoki ; Minami, Akiko ; Tsunekawa, Hiroko ; Satoyoshi, Hiroshi ; Tsukamoto, Yuka ; Takahata, Kazue ; Muraoka, Shizuko</creator><creatorcontrib>Ishikawa, Toshiko ; Okano, Motoki ; Minami, Akiko ; Tsunekawa, Hiroko ; Satoyoshi, Hiroshi ; Tsukamoto, Yuka ; Takahata, Kazue ; Muraoka, Shizuko</creatorcontrib><description>•Repeated selegiline injection reduces immobility time in rodent depression tests.•Antidepressant-like action of selegiline is independent of MAO-A inhibition.•Selegiline increases DA content and prevents LTP impairment in the hippocampus.
Selegiline, an irreversible inhibitor of monoamine oxidase (MAO)-type B, is widely prescribed for Parkinson’s disease and, at higher doses, for major and atypical depression, whereby it is non-selectively inhibitory to both MAO-A and MAO-B activities. MAO inhibitors have been considered to function as antidepressants through MAO-A inhibition. We have previously reported that selegiline exerts antidepressant-like effects in the mouse forced swim test (FST) via dopamine D1 receptor activation. Our objective was to elucidate the mechanisms underlying the antidepressant-like effects of selegiline. We also tested another propargylamine MAO-B inhibitor, rasagiline. Triple subcutaneous injection (at 24, 5, and 1 h prior to behavioral testing) with selegiline (10 mg/kg/injection), but not rasagiline (1, 3, or 10 mg/kg/injection), reduced the immobility time in the mouse FST and rat tail suspension test. In the hippocampus and prefrontal cortex of mice subjected to the FST, selegiline and rasagiline completely inhibited MAO-B activities. However, selegiline suppressed MAO-A activities and monoamine turnover rates at a lesser degree than rasagiline at the same doses, indicating that the antidepressant-like effects of selegiline are independent of MAO-A inhibition. Moreover, selegiline, but not rasagiline, increased the hippocampal dopamine content. A single subcutaneous administration of 10 mg/kg selegiline, but not of rasagiline, significantly prevented hippocampal CA1 long-term potentiation impairment, induced by low-frequency stimulation prior to high-frequency stimulation in rats. These results suggest that the antidepressant-like effects of selegiline are attributable to enhancement of dopaminergic transmission and prevention of the impairment of synaptic plasticity in the hippocampus.</description><identifier>ISSN: 0166-4328</identifier><identifier>EISSN: 1872-7549</identifier><identifier>DOI: 10.1016/j.bbr.2018.10.032</identifier><identifier>PMID: 30359642</identifier><language>eng</language><publisher>Netherlands: Elsevier B.V</publisher><subject>Depression ; Hippocampus ; Long-term potentiation ; Monoamine oxidase inhibitor ; Selegiline ; Synaptic plasticity</subject><ispartof>Behavioural brain research, 2019-02, Vol.359, p.353-361</ispartof><rights>2018 The Authors</rights><rights>Copyright © 2018 The Authors. Published by Elsevier B.V. All rights reserved.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c396t-f55987bfeb1db98ea5db051eb824d3cd0a4bca765d800463dc8c8f4a0a3b18c63</citedby><cites>FETCH-LOGICAL-c396t-f55987bfeb1db98ea5db051eb824d3cd0a4bca765d800463dc8c8f4a0a3b18c63</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S016643281831235X$$EHTML$$P50$$Gelsevier$$Hfree_for_read</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/30359642$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Ishikawa, Toshiko</creatorcontrib><creatorcontrib>Okano, Motoki</creatorcontrib><creatorcontrib>Minami, Akiko</creatorcontrib><creatorcontrib>Tsunekawa, Hiroko</creatorcontrib><creatorcontrib>Satoyoshi, Hiroshi</creatorcontrib><creatorcontrib>Tsukamoto, Yuka</creatorcontrib><creatorcontrib>Takahata, Kazue</creatorcontrib><creatorcontrib>Muraoka, Shizuko</creatorcontrib><title>Selegiline ameliorates depression-like behaviors in rodents and modulates hippocampal dopaminergic transmission and synaptic plasticity</title><title>Behavioural brain research</title><addtitle>Behav Brain Res</addtitle><description>•Repeated selegiline injection reduces immobility time in rodent depression tests.•Antidepressant-like action of selegiline is independent of MAO-A inhibition.•Selegiline increases DA content and prevents LTP impairment in the hippocampus.
Selegiline, an irreversible inhibitor of monoamine oxidase (MAO)-type B, is widely prescribed for Parkinson’s disease and, at higher doses, for major and atypical depression, whereby it is non-selectively inhibitory to both MAO-A and MAO-B activities. MAO inhibitors have been considered to function as antidepressants through MAO-A inhibition. We have previously reported that selegiline exerts antidepressant-like effects in the mouse forced swim test (FST) via dopamine D1 receptor activation. Our objective was to elucidate the mechanisms underlying the antidepressant-like effects of selegiline. We also tested another propargylamine MAO-B inhibitor, rasagiline. Triple subcutaneous injection (at 24, 5, and 1 h prior to behavioral testing) with selegiline (10 mg/kg/injection), but not rasagiline (1, 3, or 10 mg/kg/injection), reduced the immobility time in the mouse FST and rat tail suspension test. In the hippocampus and prefrontal cortex of mice subjected to the FST, selegiline and rasagiline completely inhibited MAO-B activities. However, selegiline suppressed MAO-A activities and monoamine turnover rates at a lesser degree than rasagiline at the same doses, indicating that the antidepressant-like effects of selegiline are independent of MAO-A inhibition. Moreover, selegiline, but not rasagiline, increased the hippocampal dopamine content. A single subcutaneous administration of 10 mg/kg selegiline, but not of rasagiline, significantly prevented hippocampal CA1 long-term potentiation impairment, induced by low-frequency stimulation prior to high-frequency stimulation in rats. These results suggest that the antidepressant-like effects of selegiline are attributable to enhancement of dopaminergic transmission and prevention of the impairment of synaptic plasticity in the hippocampus.</description><subject>Depression</subject><subject>Hippocampus</subject><subject>Long-term potentiation</subject><subject>Monoamine oxidase inhibitor</subject><subject>Selegiline</subject><subject>Synaptic plasticity</subject><issn>0166-4328</issn><issn>1872-7549</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><recordid>eNp9kM1uFDEQhC0EIpvAA3BBPnKZxR7Pj0ecUBQgUiQOwNlq2z2JF49t7NlI-wS8Nt7dwJFTy-6qUtdHyBvOtpzx4f1uq3XetozL-t4y0T4jGy7Hthn7bnpONlUzNJ1o5QW5LGXHGOtYz1-SC8FEPw1duyG_v6HHe-ddQAoLehczrFioxZSxFBdD491PpBof4LEuC3WB5mgxrIVCsHSJdu9PlgeXUjSwJPDUxgRLzcz3ztA1QyiLO6WdPOUQIK11kzyUOt16eEVezOALvn6aV-THp5vv11-au6-fb68_3jVGTMPazH0_yVHPqLnVk0Tora6VUMu2s8JYBp02MA69lbXsIKyRRs4dMBCaSzOIK_LunJty_LXHsqp6mEHvIWDcF9Xydpg4Z6OoUn6WmhxLyTirlN0C-aA4U0f-aqcqf3Xkf_yq_Kvn7VP8Xi9o_zn-Aq-CD2cB1pKPDrMqxmEwaF1Gsyob3X_i_wC6MZrR</recordid><startdate>20190201</startdate><enddate>20190201</enddate><creator>Ishikawa, Toshiko</creator><creator>Okano, Motoki</creator><creator>Minami, Akiko</creator><creator>Tsunekawa, Hiroko</creator><creator>Satoyoshi, Hiroshi</creator><creator>Tsukamoto, Yuka</creator><creator>Takahata, Kazue</creator><creator>Muraoka, Shizuko</creator><general>Elsevier B.V</general><scope>6I.</scope><scope>AAFTH</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20190201</creationdate><title>Selegiline ameliorates depression-like behaviors in rodents and modulates hippocampal dopaminergic transmission and synaptic plasticity</title><author>Ishikawa, Toshiko ; Okano, Motoki ; Minami, Akiko ; Tsunekawa, Hiroko ; Satoyoshi, Hiroshi ; Tsukamoto, Yuka ; Takahata, Kazue ; Muraoka, Shizuko</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c396t-f55987bfeb1db98ea5db051eb824d3cd0a4bca765d800463dc8c8f4a0a3b18c63</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Depression</topic><topic>Hippocampus</topic><topic>Long-term potentiation</topic><topic>Monoamine oxidase inhibitor</topic><topic>Selegiline</topic><topic>Synaptic plasticity</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ishikawa, Toshiko</creatorcontrib><creatorcontrib>Okano, Motoki</creatorcontrib><creatorcontrib>Minami, Akiko</creatorcontrib><creatorcontrib>Tsunekawa, Hiroko</creatorcontrib><creatorcontrib>Satoyoshi, Hiroshi</creatorcontrib><creatorcontrib>Tsukamoto, Yuka</creatorcontrib><creatorcontrib>Takahata, Kazue</creatorcontrib><creatorcontrib>Muraoka, Shizuko</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Behavioural brain research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ishikawa, Toshiko</au><au>Okano, Motoki</au><au>Minami, Akiko</au><au>Tsunekawa, Hiroko</au><au>Satoyoshi, Hiroshi</au><au>Tsukamoto, Yuka</au><au>Takahata, Kazue</au><au>Muraoka, Shizuko</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Selegiline ameliorates depression-like behaviors in rodents and modulates hippocampal dopaminergic transmission and synaptic plasticity</atitle><jtitle>Behavioural brain research</jtitle><addtitle>Behav Brain Res</addtitle><date>2019-02-01</date><risdate>2019</risdate><volume>359</volume><spage>353</spage><epage>361</epage><pages>353-361</pages><issn>0166-4328</issn><eissn>1872-7549</eissn><abstract>•Repeated selegiline injection reduces immobility time in rodent depression tests.•Antidepressant-like action of selegiline is independent of MAO-A inhibition.•Selegiline increases DA content and prevents LTP impairment in the hippocampus.
Selegiline, an irreversible inhibitor of monoamine oxidase (MAO)-type B, is widely prescribed for Parkinson’s disease and, at higher doses, for major and atypical depression, whereby it is non-selectively inhibitory to both MAO-A and MAO-B activities. MAO inhibitors have been considered to function as antidepressants through MAO-A inhibition. We have previously reported that selegiline exerts antidepressant-like effects in the mouse forced swim test (FST) via dopamine D1 receptor activation. Our objective was to elucidate the mechanisms underlying the antidepressant-like effects of selegiline. We also tested another propargylamine MAO-B inhibitor, rasagiline. Triple subcutaneous injection (at 24, 5, and 1 h prior to behavioral testing) with selegiline (10 mg/kg/injection), but not rasagiline (1, 3, or 10 mg/kg/injection), reduced the immobility time in the mouse FST and rat tail suspension test. In the hippocampus and prefrontal cortex of mice subjected to the FST, selegiline and rasagiline completely inhibited MAO-B activities. However, selegiline suppressed MAO-A activities and monoamine turnover rates at a lesser degree than rasagiline at the same doses, indicating that the antidepressant-like effects of selegiline are independent of MAO-A inhibition. Moreover, selegiline, but not rasagiline, increased the hippocampal dopamine content. A single subcutaneous administration of 10 mg/kg selegiline, but not of rasagiline, significantly prevented hippocampal CA1 long-term potentiation impairment, induced by low-frequency stimulation prior to high-frequency stimulation in rats. These results suggest that the antidepressant-like effects of selegiline are attributable to enhancement of dopaminergic transmission and prevention of the impairment of synaptic plasticity in the hippocampus.</abstract><cop>Netherlands</cop><pub>Elsevier B.V</pub><pmid>30359642</pmid><doi>10.1016/j.bbr.2018.10.032</doi><tpages>9</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0166-4328 |
ispartof | Behavioural brain research, 2019-02, Vol.359, p.353-361 |
issn | 0166-4328 1872-7549 |
language | eng |
recordid | cdi_proquest_miscellaneous_2126911073 |
source | Elsevier ScienceDirect Journals |
subjects | Depression Hippocampus Long-term potentiation Monoamine oxidase inhibitor Selegiline Synaptic plasticity |
title | Selegiline ameliorates depression-like behaviors in rodents and modulates hippocampal dopaminergic transmission and synaptic plasticity |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-01T15%3A50%3A53IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Selegiline%20ameliorates%20depression-like%20behaviors%20in%20rodents%20and%20modulates%20hippocampal%20dopaminergic%20transmission%20and%20synaptic%20plasticity&rft.jtitle=Behavioural%20brain%20research&rft.au=Ishikawa,%20Toshiko&rft.date=2019-02-01&rft.volume=359&rft.spage=353&rft.epage=361&rft.pages=353-361&rft.issn=0166-4328&rft.eissn=1872-7549&rft_id=info:doi/10.1016/j.bbr.2018.10.032&rft_dat=%3Cproquest_cross%3E2126911073%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2126911073&rft_id=info:pmid/30359642&rft_els_id=S016643281831235X&rfr_iscdi=true |